Yuanfang Li

Yuanfang Li

Auto-generated profile, based on publicly available information

Yuanfang Li

Institute for Cardiovascular Prevention, Ludwig-Maximilians-Universität München (LMU), Munich, Germany

Research Focus & Metrics

Academic Career Length

13Years (2014-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
27 April 2022 in Nature
Verified
Journal Article
Closed access
PDF file
SMSarajo Mohanta
Sarajo Mohanta
LPLi Peng
Li Peng
YLYuanfang Li
Yuanfang Li
SLShu Lu
Shu Lu
TSTing Sun
Ting Sun
AHAndreas JR Habenicht
Andreas JR Habenicht

21 May 2014 in Scientific Reports
Verified
Journal Article
Open access
JWJichuang Wang
Jichuang Wang
Jiang ZhouJiang Zhou
Jiang Zhou
LXLiping Xiang
Liping Xiang
YLYuanfang Li
Yuanfang Li
MOMinrui Ou
Minrui Ou
LJLee Jia
Lee Jia
Ursolic acid (UA) is a naturally bioactive product that exhibits potential anticancer effects. The relatively safe and effective molecule intrigued us to explore a way to further improve its anti-cancer activity and tumor-targeting specificity. In the present study, a series of structural modifications of UA was achieved, which resulted in significant increase in growth inhibition on various cancer cell lines with minimal effects on normal cells. The leading molecule US597 (UA-4) caused depolarization of mitochondrial membrane potential, cell arrest in G0/G1 phase and apoptosis/necrosis in a dose-dependent manner. Structural docking suggested that the carbon chains of the modified UA derivatives compete strongly with glucose for binding to glucokinase, the key glycolysis enzyme presumably active in cancer cells. The combination of 2-deoxy-D-glucose (2-DG) and UA-4 induced cell cycle arrest in G2/M phase, promoted caspase-dependent cell death, reduced hexokinase activity, aggravated depletion of intracellular ATP, decreased lactate production and synergistically inhibited cancer cell growth in vitro (HepG2) and in vivo (H22). Collectively, our findings suggest that the structural modification enhances efficacy and selectivity of UA, and the combination of UA-4 with 2-DG produces synergistic inhibition on hepatoma cell proliferation by dual targeting of apoptosis and glycolysis.

30 September 2022 in Circulation Research
Verified
Journal Article
Closed access
PDF file
KNKatrin Nitz
Katrin Nitz
MLMichael Lacy
Michael Lacy
MBMariaelvy Bianchini
Mariaelvy Bianchini
KWKanin Wichapong
Kanin Wichapong
IKIrem Avcilar Kücükgöze
Irem Avcilar Kücükgöze
DADorothee Atzler
Dorothee Atzler
Background: Amino acid metabolism is crucial for inflammatory processes during atherogenesis. The endogenous amino acid homoarginine is a robust biomarker for cardiovascular outcome and mortality with high levels being protective. However, the underlying mechanisms remain elusive. We investigated the effect of homoarginine supplementation on atherosclerotic plaque development with a particular focus on inflammation. Methods: Female ApoE-deficient mice were supplemented with homoarginine (14 mg/L) in drinking water starting 2 weeks before and continuing throughout a 6-week period of Western-type diet feeding. Control mice received normal drinking water. Immunohistochemistry and flow cytometry were used for plaque- and immunological phenotyping. T cells were characterized using mass spectrometry–based proteomics, by functional in vitro approaches, for example, proliferation and migration/chemotaxis assays as well as by super-resolution microscopy. Results: Homoarginine supplementation led to a 2-fold increase in circulating homoarginine concentrations. Homoarginine-treated mice exhibited reduced atherosclerosis in the aortic root and brachiocephalic trunk. A substantial decrease in CD3 + T cells in the atherosclerotic lesions suggested a T-cell–related effect of homoarginine supplementation, which was mainly attributed to CD4 + T cells. Macrophages, dendritic cells, and B cells were not affected. CD4 + T-cell proteomics and subsequent pathway analysis together with in vitro studies demonstrated that homoarginine profoundly modulated the spatial organization of the T-cell actin cytoskeleton and increased filopodia formation via inhibition of Myh9 (myosin heavy chain 9). Further mechanistic studies revealed an inhibition of T-cell proliferation as well as a striking impairment of the migratory capacities of T cells in response to relevant chemokines by homoarginine, all of which likely contribute to its atheroprotective effects. Conclusions: Our study unravels a novel mechanism by which the amino acid homoarginine reduces atherosclerosis, establishing that homoarginine modulates the T-cell cytoskeleton and thereby mitigates T-cell functions important during atherogenesis. These findings provide a molecular explanation for the beneficial effects of homoarginine in atherosclerotic cardiovascular disease.

14 May 2019 in Chemical Science
Verified
Journal Article
Open access
PDF file
TLThomas Linder
Thomas Linder
RLRongxia Liu
Rongxia Liu
Atanas G. AtanasovAtanas G. Atanasov
Atanas G. Atanasov
YLYuanfang Li
Yuanfang Li
SGSophie Geyrhofer
Sophie Geyrhofer
MMMarko D. Mihovilovic
Marko D. Mihovilovic
Recently, a natural compound leoligin, a furan-type lignan, was discovered as an interesting hit compound with an anti-inflammatory pharmacological activity profile. We developed a modular and stereoselective approach for the synthesis of the edelweiss-derived lignan leoligin and used the synthetic route to rapidly prepare leoligin analogs even on the gram scale. Proof of concept of this approach together with cell-based bio-assays gained structural analogs with increased selectivity towards vascular smooth muscle versus endothelial cell proliferation inhibition, a major benefit in fighting vascular neointima formation. In addition, we identified the structural features of leoligin analogs that define their ability to inhibit the pro-inflammatory NF-κB pathway. Results are discussed in the context of structural modification of these novel synthetic lignans.

17 December 2025 in Nature
Verified
Journal Article
Open access
PDF file
SMSarajo Mohanta
Sarajo Mohanta
LPLi Peng
Li Peng
YLYuanfang Li
Yuanfang Li
SLShu Lu
Shu Lu
TSTing Sun
Ting Sun
AHAndreas JR Habenicht
Andreas JR Habenicht